AI-Powered Prostate Cancer Detection in Clinical Trial
Three English Hospitals Join Forces to Test AI Technology
Three hospital systems across England have embarked on a live clinical trial to assess the effectiveness of AI technology in detecting and grading prostate cancer. The study, known as ARTICULATE PRO, is being led by the University of Oxford in collaboration with Paige, a pioneer in clinical AI applications for cancer diagnosis.
About the Trial
The participating hospitals – North Bristol Trust Southmead Hospital, University Hospitals Coventry and Warwickshire, and Oxford University NHS Foundation Trust – are incorporating Paige’s AI technology into their standard of care. The multisite trial aims to evaluate the potential of AI to improve patient outcomes against a backdrop of rising prostate cancer cases.
Professor Clare Verrill’s Comments
Professor Clare Verrill, OUH Cellular Pathology Consultant, Associate Professor, and Principal Investigator of ARTICULATE PRO, emphasizes the central focus on patients: “We are striving towards our goal to safely and effectively ensure they benefit the most from powerful AI technology. With the multisite live use of The Paige Prostate Suite, we can systematically study benefits to patients in clinical settings.”
How the AI Works
The Prostate Suite – the AI system being trialled – is designed to assist pathologists in detecting, grading, and measuring tumours in prostate biopsies and tissue samples. Pathologists at the three hospitals are assessing how this AI technology impacts their clinical decision-making, pathology service delivery, and resource utilisation in real-world settings.
Expert Insights
Dr. Jon Oxley, Uropathologist and Bristol lead of ARTICULATE PRO, notes: “I have studied the disease and progression of prostate cancer in clinical research for over 25 years. It is a significant advancement that Paige’s AI applications have achieved a level of validation and performance that allows safe and effective live clinical use. Using Paige Prostate Suite alongside our standard of care has the promise to increase efficiency and improve reproducibility of results for patients.”
Dr. Bidisa Sinha, Uropathologist at University Hospitals Coventry and Warwickshire, adds: “We believe AI can help to improve the accuracy and consistency of grading cancer and assist in detection of small areas of cancer which are easy to miss. This is world-leading research being carried out at UHCW. We are proud to be a global leader in the field of digital and computational pathology.”
Funding and Future Outcomes
The ARTICULATE PRO study is funded by the Accelerated Access Collaborative (AAC) Artificial Intelligence in Health and Care Award, overseen by the Department of Health and Social Care. As prostate cancer rates continue to rise, the integration of AI in diagnosis could potentially lead to earlier detection, more accurate grading, and ultimately improved patient outcomes. The results of this trial could pave the way for wider adoption of AI in cancer diagnosis across the UK and beyond.
Conclusion
The integration of AI in cancer diagnosis has the potential to revolutionize the way healthcare professionals detect and treat various types of cancer. With the ARTICULATE PRO study, experts aim to push the boundaries of what is possible in terms of patient outcomes and accuracy of diagnosis. As the trial continues, we can expect to see significant advancements in the field of AI-powered cancer detection and grading.
FAQs
* What is the purpose of the ARTICULATE PRO study?
The study aims to evaluate the effectiveness of AI technology in detecting and grading prostate cancer in clinical settings.
* How many hospitals are participating in the study?
Three hospital systems across England are participating in the study: North Bristol Trust Southmead Hospital, University Hospitals Coventry and Warwickshire, and Oxford University NHS Foundation Trust.
* What is the potential impact of AI in cancer diagnosis?
The integration of AI in diagnosis could lead to earlier detection, more accurate grading, and improved patient outcomes in the fight against cancer.
